

Name of the Issuer:	GPT Healthcare Limited	Last updated on	31-May-25
---------------------	------------------------	-----------------	-----------

1	Type of Issue (PO / FPO)	IPO
---	--------------------------	-----

2	Issue Size (Rs. Cr)	525.14
	- Fresh Issue Size (Rs. Cr)	40.00
	- Offer for Sale Component (Rs. Cr)	485.14
	Source: Final Post Issue Report dated March 5, 2024	

3	Grade of issue along with name of the rating agency	
	Name	Not Applicable
	Grade	Not Applicable

4	Subscription Level (Number of times)	6.2800 [*]
	Source: Final Post Issue Report dated March 5, 2024	
	[*] The above figure is after technical rejections, multiple or duplicate bids and bids not banked/rejected	

5	OIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
	Particulars	%
	(i) allotment in the issue	17.20%
	(ii) at the end of the 1 st Quarter immediately after the listing of the issue (February 28, 2024)	12.81%
	(iii) at the end of 1 st FY (March 31, 2024) [*]	12.81%
	(iv) at the end of 2 nd FY (March 31, 2025) [*]	15.83%
	(v) at the end of 3 rd FY (March 31, 2026) [*]	Not Available
	[*] Period not completed	
	[*] Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024	

6	Financials of the Issuer	
	(In Rs. Crore)	
	Parameters	1 st FY (March 31, 2024)
		2 nd FY (March 31, 2025)
		3 rd FY (March 31, 2026) [*]
	Income from operations	400.19
		407.09
		Not Available
	Net Profit for the period	47.77
		49.92
		Not Available
	Paid-up equity share capital	82.06
		82.06
		Not Available
	Reserves excluding revaluation reserves	1,364.35
		165.79
		Not Available
	[*] Period not completed	

7	Trading Status in the scrip of the Issuer	
	Company's Equity Shares are listed on both the BSE Limited and NSE. The Shares have not been suspended or delisted.	
	Particulars	Status
	(i) at the end of 1 st FY (March 31, 2024)	Frequently Traded
	(ii) at the end of 2 nd FY (March 31, 2025)	Frequently Traded
	(iii) at the end of 3 rd FY (March 31, 2026) [*]	Not Available
	[*] Period not completed	

8	Change in Directors of Issuer from the disclosures in the offer document	
	Particulars	Name of the Director
		Appointed / Resigned
	(i) at the end of 1 st FY (March 31, 2024)	a) Mr. Dwarka Prasad Tantiya
		b) Mr. Anurag Tantiya
		Re-appointment
	(ii) at the end of 2 nd FY (March 31, 2025)	a) Mr. Dwarka Prasad Tantiya
		b) Mr. Anurag Tantiya
		Re-appointment
	(iii) at the end of 3 rd FY (March 31, 2026) ^{**}	Not Available
		Not Available
	Source: Stock Exchange Filings	
	^{**} Re-appointment as on 1 st October , 2024	

9	Status of implementation of project/ commencement of commercial production	
	(i) as disclosed in the offer document	Not applicable
	(ii) Actual implementation	Not applicable
	(iii) Reasons for delay in implementation, if any	Not applicable

10	Status of utilization of issue proceeds	
	(i) as disclosed in the offer document	
	(In Rs. Crore)	
	Particulars	Amount proposed to be funded from Net Proceeds
		Estimated Deployment (Financial Year 2024)
		Estimated Deployment (Financial Year 2025)
	Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	30.00
		20.00
		10.00
	General Corporate Purposes	7.52
		4.52
		3.00
	Source: Prospectus dated February 26, 2024	
	(ii) Actual utilization	
	(In Rs. Crore)	
	Particulars	As of March 31, 2024
	Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company from banks and financial institutions	30.00
	General Corporate Purposes	7.52
	[#] Source: Stock Exchange Intimation of statement of deviation/ variation dated May 21, 2024	
	(iii) Reasons for deviation, if any	Not applicable

11	Comments of monitoring agency, if applicable ^a	
	(a) Comments on use of funds	Not Applicable
	(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
	(c) Any other reservations expressed by the monitoring agency about the end use of funds	
^a Monitoring Agency is not applicable since the fresh issue size is less than Rs. 100 crores		

12	Pricing Data	
	Issue Price (Rs.):	186
	Designated Stock Exchange:	BSE
	Listing Date:	29-Feb-24

Price parameters	At close of listing day (Feb 29, 2024)	At close of 30th calendar day from listing day (Mar 29, 2024) ⁽¹⁾	At close of 90th calendar day from listing day May 28, 2024 ⁽²⁾	As at the end of 1 st FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾		As at the end of 2 nd FY after the listing of the issue (March 31, 2025) ⁽⁵⁾⁽⁴⁾		As at the end of 3 rd FY after the listing of the issue (March 31, 2026) ⁽⁶⁾⁽⁴⁾	
				Closing price	High (during the FY)	Closing price	High (during the FY)	Closing price	High (during the FY)
Market Price on Designated Stock Exchange	200.75	176.45	147.55	176.45	219.70	139.80	146.70	149.40	134.10
BSE SENSEX	22,609.30	73,651.35	75,170.45	73,651.35	74,245.17	71,674.42	77,756.70	77,185.62	Not available
BSE HEALTHCARE ⁽⁷⁾	85,079.32	95,052.84	95,062.18	95,052.84	95,142.21	93,389.29	41,421.50	41,609.39	41,185.44

- Note:
- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
- (2) 90th calendar day shall be taken as listing date plus 89 calendar days. Since 90th calendar day is a Saturday, the next trading day is considered.
- (3) High and Low based on intra day prices.
- (4) Pricing data not disclosed as the relevant fiscal year and period have not completed.
- (5) BSE HEALTHCARE Index represents the relevant sectoral index
- (6) Given that the Company was listed on Feb 29, 2024, the data is presented for the period beginning on Feb 29, 2024
- (7) In case of reporting date falling on a trading holiday, values for the trading day immediately preceding the trading holiday has been considered

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽ⁱ⁾	1st FY (March 31, 2024)	2nd FY (March 31, 2025)	3rd FY (March 31, 2026) ^(j)
EPS	Issuer:			
	Basic	4.88	43.29	6.08
	Peer Group:			
	Global Health Limited	12.58	52.04	17.92
	Krishna Institute of Medical Sciences Limited	42.03	29.41	2.22
	Jupiter Life Line Hospitals Limited	13.96	28.65	Not reported
	Yashwanth Hospital & Trauma Care Services Limited	10.09	14.46	14.72
	Kova Medical Center & Hospital Limited	105.80	164.25	190.95
	Shaby Limited	6.31	9.67	7.80
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable
PE	Issuer:			
	Basic	NA	9.26	Not Available
	Peer Group:			
	Global Health Limited	90.29	17.58	63.40
	Krishna Institute of Medical Sciences Limited	49.51	69.98	73.50
	Jupiter Life Line Hospitals Limited	81.73	41.81	54.50
	Yashwanth Hospital & Trauma Care Services Limited	37.66	28.86	28.70
	Kova Medical Center & Hospital Limited	29.93	22.78	27.50
	Shaby Limited	49.01	24.75	25.27
	Industry Avg:	56.36	34.29	45.48
RoNW (%)	Issuer:			
	Basic	23.77	16.70	20.14
	Peer Group:			
	Global Health Limited	13.56	5.15	14.19
	Krishna Institute of Medical Sciences Limited	20.35	12.61	20.20
	Jupiter Life Line Hospitals Limited	19.94	15.11	14.24
	Yashwanth Hospital & Trauma Care Services Limited	36.06	17.94	8.13
	Kova Medical Center & Hospital Limited	16.11	20.23	20.31
	Shaby Limited	7.33	14.90	9.78
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable
NAV per share	Issuer:			
	Basic	20.54	230.74	30.21
	Peer Group:			
	Global Health Limited	89.65	326.88	620.42
	Krishna Institute of Medical Sciences Limited	206.47	233.31	267.25
	Jupiter Life Line Hospitals Limited	64.70	178.16	205.61
	Yashwanth Hospital & Trauma Care Services Limited	27.84	101.78	120.31
	Kova Medical Center & Hospital Limited	656.65	815.17	812.02
	Shaby Limited	85.54	98.90	98.89
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable

Notes:

(i) Sourced from Prospectus dated Feb 26, 2024.

(j) Period not over

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) EPS (Rs.) is Profit after tax attributable to equity shareholders for the year divided by Weighted average number of Equity Shares outstanding during the year / period

(ii) P/E - Closing Market Price as of relevant fiscal year and or period / EPS

(iii) RoNW - Return on net worth % is computed as net profit after tax attributable to owners of the holding company divided by net-worth excluding non controlling interest

(iv) NAV per share - NAV is computed as net worth divided by number of equity shares outstanding.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
17 March 2024	Search operation was carried out by Income Tax Department on the locations of the Company from March 14, 2024 to March 17, 2024. We hereby inform that all stock of inventory, cash and other assets were found to be duly recorded and no unaccounted cash or transactions have been found by the authorities. The search team has not seized anything incriminating.
19 March 2024	- Approval of unaudited financial results along with Limited Review Report for the quarter and nine months ended Dec 31, 2023 - Appointment of Mr. Vishal Goyal as Group COO and to be considered as SMP w.e.f. April 1, 2024
19 March 2024	Declared second Interim Dividend at the rate of 10% (Rs. 1.00 per share) on the face value of the equity shares (Rs. 10/- each) of the Company, for the financial year 2023-24. The Company is expecting to pay the interim dividend to the shareholders on or before April 17, 2024. The Record Date for the purpose of payment of the aforesaid Interim Dividend has been fixed at Monday, April 01, 2024
19 March 2024	Declared the list of KMPs who will determine materiality of any event or information, going forward: - Mr. Anurag Tanti - Mrs. Kirti Tanti - Mr. Anur Sharma
19 March 2024	In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Investor Presentation for Q3FY24 was submitted for dissemination to general public and investors.
19 March 2024	Record Date for Payment of Dividend revised to April 02, 204 from April 01, 2024
09 April 2024	Postal Ballot Notice for passing special resolution for continuation of Mr. Dwarka Prasad Tanti as Chairman and Wholetime Director of the Company after attaining the age of 75 years
16 April 2024	Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 issued by Practicing Company Secretary for the year ended March 31, 2024
16 April 2024	In terms of SEBI Circular No. SEBI/HO/CHS/CIR/P/2018/144 dated November 26, 2018 with regard to fund raising by issuance of debt securities by large entities, Company does not fall under "Large Corporate" (LC) category as per the framework provided in the aforesaid circular. Therefore, the requirement of filing the disclosure and annual disclosure in Annexures A and B1 & B2 respectively to the aforesaid Circular does not arise.
25 April 2024	Pursuant to Regulation 30 read with Part A of Schedule II of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that Dr. Bharti Chattopadhyay, Chief Operating Officer of our Agartala Hospital part of the Senior Management of the Company has resigned due to personal reasons.
25 April 2024	In continuation of Memorandum of Understanding Letter of Intent dated January 16, 2023, which forms part of Material Contracts and Documents of the Company, disclosed at the time of initial public offer of the Company, entered among Sun and Sun Inframetric Private Limited, Mosaic Infraventure Private Limited and our Company is GPT Healthcare Limited. Please be informed that our Company has further entered into Lease Agreement with Sun and Sun Inframetric Private Limited and Mosaic Infraventure Private Limited on April 24, 2024.
26 April 2024	The CRN of the Company has changed from U70101WB1899PLC047402 to L70101WB1899PLC047402 by the Registrar of Companies, Kolkata, West Bengal
10 May 2024	Voting Results & Submission of Scrutinizers Report for Postal Ballot for continuation of Mr. Dwarka Prasad Tanti as Chairman and Whole Time Director of the Company upon attaining the age of 75 years
14 May 2024	Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 21, 2024 at the Registered Office of the Company, inter-alia, to consider and approve following matters: a) the Audited Financial Results along with Report of the Statutory Auditors thereon of the Company for the 4th quarter and year ended on March 31, 2024 b) the recommendation of final dividend, if any, on the equity share capital of the company for the FY 2023-24
21 May 2024	Subsequent to the above, the following events have occurred: a) Approved the Audited Financial Results (Standalone) as per IND-AS along with Auditors Report thereon for the 4 th Quarter and year ended March 31, 2024 b) Declaration of unmodified opinion by statutory auditors in their Auditors Report on the annual audited standalone financial results for the quarter and year ended March 31, 2024 c) Approved convening of 35 th Annual General Meeting on Thursday, July 25, 2024 through Video Conferencing (VC) d) Recommended Final Dividend of 15% i.e. Rs. 1.5 per equity share on the face value of Rs. 10 each for the financial year ended March 31, 2024 e) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Friday, July 19, 2024 to Thursday, July 25, 2024 (both days inclusive) for the purpose of 35 th Annual General Meeting and Dividend for the financial year 2023-24. The record (cut-off) date is Thursday, July 18, 2024 f) Approved the appointment of S.R. Buttoo & Co LLP, Chartered Accountants g) Approved the reappointment of Ashok Kumar Daga as the Secretarial Auditors of the Company for FY 2024-25 h) Approved the reappointment of S.K. Sahu & Associates as the Cost Auditors of the Company for FY 2024-25, subject to ratification of their remuneration of the shareholders of the Company. i) Approved the reappointment of Sumit Binani & Associates, Chartered Accountants and ARVS & Associates, Chartered Accountants, as Internal Auditors of the Company for the FY 2024-25 j) Approved reappointment of the following Directors, based on the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders in the ensuing 36 th Annual General Meeting of the Company: - Mr. Dwarka Prasad Tanti as Chairman & Whole Time Director for further period of 3 consecutive years w.e.f. Oct 1, 2024 - Mr. Anurag Tanti as Whole Time Director designated as the Executive Director for further period of 3 years w.e.f. Oct 1, 2024 h) Approved payment of Director Consultancy Fees to Dr. Ghandyam Goyal, Non-Executive Non-Independent Director of the Company for FY 2024-25 i) Approved revision in remuneration payable to Mrs. Kirti Tanti, Chief Financial Officer, a relative of Mr. Dwarka Prasad Tanti, Chairman of the Company, for info@sunandson.com or info@sunandson.com
23 May 2024	Annual Secretarial Compliance Report issued by Practicing Company Secretary for the year ended March 31, 2024, pursuant to Circular No. CIR/CFD/CMD/27/2019 dated February 8, 2019 issued by Securities and Exchange Board of India read with Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
14 June 2024	Announcement under Regulation 30 (LOOR)-Analyst / Investor Meet - Information - Please find enclosed herewith information for investor meet on June 19, 2024.
20 June 2024	Announcement under Regulation 30 (LOOR)-Analyst / Investor Meet - Information - Please find enclosed herewith information for investor meet on June 28, 2024.
25 June 2024	Announcement under Regulation 30 (LOOR)-Newspaper Publication - Please find enclosed herewith copies of News Paper Publication pertaining to information on 36 th Annual General Meeting of the Company.
25 June 2024	Information Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (As Amended)

25 June 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for investor meet on June 28, 2024.
26 June 2024	Closure of Trading Window - Please find enclosed herewith intimation for the closure of trading window w.e.f Monday, July 1, 2024 until 48 hours from the declaration of Financial Results for the Q.E. June 30, 2024.
01 July 2024	Shareholders Meeting-35Th AGM On Thursday, July 25, 2024 - Please find enclosed herewith Notice of 35th AGM of the Company.
01 July 2024	Reg. 34 (1) Annual Report - Please find enclosed herewith the Annual Report including Notice of 35th Annual General Meeting of the Company.
02 July 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith News Paper Publication related to 35th AGM of the Company.
04 July 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith intimation for Investor Meet on Tuesday, July 09, 2024.
15 July 2024	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter Ended June 30, 2024.
25 July 2024	Shareholder Meeting / Postal Ballot-Outcome of AGM - Please find the Outcome of the 35th Annual General Meeting of GPT Healthcare Limited Held on July 25, 2024.
26 July 2024	Shareholder Meeting / Postal Ballot-Scrutinizer's Report - Please find the enclosed Voting Results and Scrutinizer Report on 35th AGM of the Company.
07 August 2024	Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Along With Report Of The Statutory Auditors Thereon Of The Company For The 1st Quarter Ended June 30, 2024 - GPT Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024, inter alia, to consider and approve Un-audited Financial Results along with Report of the Statutory Auditors thereon of the Company for the 1st quarter ended June 30, 2024.
07 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith the invitation for the Earnings call for the 1st quarter ended June 30, 2024.
13 August 2024	Board Meeting Outcome for Outcome Of The Board Meeting Held On August 13, 2024
13 August 2024	Submission Of Un-Audited Financial Results For The Quarter Ended June 30, 2024
13 August 2024	Announcement under Regulation 30 (LODR)-Investor Presentation - Please find enclosed herewith the Investor Presentation for Q1 FY 2025.
13 August 2024	Announcement under Regulation 30 (LODR)-Press Release / Media Release - Please find press release on the Quarterly Results for Q1 FY 2025.
13 August 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find enclosed herewith News Paper Publication of Q1 FY 2025 Financial Results.
14 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome - Please find the Audio Link of Investor Call on the financial performance of the Company for the 1st quarter ended June 30, 2024.
16 August 2024	Announcement under Regulation 30 (LODR)-Earnings Call Transcript - Please find enclosed herewith the transcript of the earnings call held on August 14, 2024 to discuss the Q1 FY2025 result.
22 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find the enclosed intimation for investor meet on August 27, 2024.
29 August 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed intimation for investor meet on September 4, 2024.
14 October 2024	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 - Please find enclosed herewith the Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the Q.E. September 30, 2024.
04 November 2024	Board Meeting Intimation for Considering Inter Alia And Approving The Unaudited Financial Results (Standalone) Of The Company For The 2nd Quarter And Half Year Ended On September 30, 2024 And To Declare Interim Dividend For The Financial Year 2024-25.
06 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation - Please find enclosed herewith the invitation for the Earnings call for the 2nd quarter and half year ended September 30, 2024.
14 November 2024	Board Meeting Outcome for Q2FY25 Results - Please find the outcome of the Board Meeting dated November 14, 2024.
14 November 2024	Results-Financial Results For 2nd Quarter And Half Year Ended September 30, 2024 - Please find the Q2FY25 Results
14 November 2024	Corporate Action-Board approves Dividend - Please find the intimation of Record date for the First interim Dividend for the FY 2024-25.
14 November 2024	Announcement under Regulation 30 (LODR)-Press Release / Media Release - Please find the Press Release on the Q2FY25 results.
14 November 2024	Announcement under Regulation 30 (LODR)-Investor Presentation - Please find the Investor Presentation for Q2FY25 Results.
15 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome - Please find the Audio Recording of the Investor Call held on November 14, 2024.
16 November 2024	Announcement under Regulation 30 (LODR)-Newspaper Publication - Please find the News Paper Publication on Q2FY25 Results and Notice of Record Date.
19 November 2024	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
21 November 2024	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
05 December 2024	Announcement under Regulation 30 (LODR)-Memorandum of Understanding/Agreements
27 December 2024	Closure of Trading Window
03 January 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 January 2025	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
22 January 2025	Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone) Along With Limited Review Report Of The Statutory Auditor Thereon Of The Company For The 3rd Quarter Ended On December 31, 2024.
07 February 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 February 2025	Board Meeting Outcome for Outcome Of The Board Meeting Dated February 11, 2025.
11 February 2025	Results-Financial Results For The 3rd Quarter Ended December 31, 2024
11 February 2025	Integrated Filing (Financial)
11 February 2025	Announcement under Regulation 30 (LODR)-Investor Presentation
11 February 2025	Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 February 2025	Announcement under Regulation 30 (LODR)-Newspaper Publication
12 February 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 February 2025	Announcement under Regulation 30 (LODR)-Earnings Call Transcript
21 March 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27 March 2025	Closure of Trading Window
28 March 2025	Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
10 April 2025	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

18 April 2025	Intimation Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ("LODR Regulations") Change In The Correspondence Details Of Registrar And Share Transfer Agent (RTA) Of The Company
02 May 2025	Intimation Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ("LODR Regulations")
11 May 2025	Intimation Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ("LODR Regulations")
14 May 2025	Board Meeting Intimation for Considering Inter Alia Audited Financial Results For The Quarter And Year Ended March 31, 2025.
21 May 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 May 2025	Board Meeting Outcome for Board Meeting Outcome Held On May 23, 2025
23 May 2025	Results-Financial Results For The Q4FY2025
23 May 2025	Corporate Action-Flexis Book Closure For 36Th Annual General Meeting.
23 May 2025	Corporate Action-Board approves Dividend
23 May 2025	Announcement under Regulation 30 (LODR)-Investor Presentation
23 May 2025	Announcement under Regulation 30 (LODR)-Press Release / Media Release
24 May 2025	Compliance-Reg.24(A)-Annual Secretarial Compliance
24 May 2025	Announcement under Regulation 30 (LODR)-Newspaper Publication
24 May 2025	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
26 May 2025	Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Notes:
The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.
For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and/ or www.nseindia.com

Disclaimer:
The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MRD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/ or the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information/ clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.